BayOConnect 2026

BayOConnect 2026
Go back

Discover the future of biotechnology at BioM’s networking conference BayOConnect in Munich on 30 June – 1 July 2026!

This year, BayOConnect once again brings together visionary minds, cutting-edge companies and life-science enthusiasts from Bavaria and around Europe.

The 2026 edition will focus on

  • European capital and agenda to unlock biotech success stories
  • highlighting high-potential TechBio innovation and excellence initiatives in life sciences
  • as well as international collaboration within Europe and beyond

BayOConnect – Forum for Biotech & LifeScience

As a central platform, BayOConnect accelerates progress in biotechnology and medicine by creating direct exchange between science, industry, investors and policy leaders.

Join inspiring keynotes from academia and industry, panel discussions, dynamic start-up pitches, poster sessions and high-energy networking opportunities. Whether you’re driving biopharmaceutical innovation, exploring digital and AI-enabled solutions, building strategic partnerships or seeking investment insights, BayOConnect 2026 is your gateway into Bavaria’s vibrant biotech ecosystem.

Your Benefits:

  • Dive into the intersection of cutting-edge biopharmaceuticals, Artificial Intelligence, data science, nanotechnology and more.
  • Immerse yourself in dynamic keynotes, panel discussions, and a thrilling start-up pitch.
  • Connect with industry leaders, investors, visionary scientists via partnering system partneringONE™
  • Explore the potential of innovation in the heart of Europe’s biotech hub.

Don’t miss your chance to shape the future of biotech at BayOConnect 2026 right in Munich’s dynamic innovation landscape!

BioRN members receive a 15 % discount.

Please contact Nicole Hecht (nh(at)biorn.org) for the Discount Code and more Information.

register now

Our latest News

discover more
New Publication from Sciomics GmbH: Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells

New Publication from Sciomics GmbH: Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells

Nagel, A.; Hass, E.W.; Hayes, H.; Huelbes, L.; Oliveira, S.; Hardin, H.M.; Marasigan, M.; Nisenbaum, E.; Misztal, C.; Telischi, F.F.; et al. Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells. Int. J. Mol. Sci. 2026, 27, 2636. https://doi.org/10.3390/ijms27062636 https://www.mdpi.com/1422-0067/27/6/2636 Simple Summary This study focuses on the action of fimepinostat, a dual histone deacetylase (HDAC)/phosphosphoinositide-3 kinase […]

read more
Fraunhofer IPA wins the “euRobotics Technology Transfer Award” together with Trumpf and Lorch

Fraunhofer IPA wins the “euRobotics Technology Transfer Award” together with Trumpf and Lorch

Technology transfer that works: At the “European Robotics Forum” (ERF) in late March, the trio of applicants won the prestigious award. The award recognizes research that has found its way into industrial applications. The application focused on a “no-code” solution that allows companies to deploy cobots without specialized knowledge or significant welding effort, even for […]

read more
Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Paris and Tarrytown, NY, April 13, 2026. The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged two to 11 years with inadequate response to histamine-1 […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp